ABSTRACT
INTRODUCTION
Earlier studies have shown that the oligosaccharide moieties of glycoproteins play crucial roles in a variety of cellular processes. Protein glycosylation modifies many of the characteristics of the protein core, including its secretion, stability, clearance, interactions with receptors or ligands and oligomerization (13) .
Introduction of N -glycosylation sequence(s) into selected proteins, by intentional substitution or insertion of amino acids, has provided substantial information about the functions of oligosaccharides in glycoproteins and about the structures of the core proteins. Such studies have included: (i) investigation of the two-dimensional topological arrangement of intrinsic membrane proteins in the lipid bilayer (12) ; (ii) restoration of lectin activity by introduction of a novel N -glycosylation sequence into a nonactive, nonglycosylated ricin B chain mutant (14) ; (iii) mapping domains for ligand binding by a low-affinity nerve growth factor receptor (p75) (1); and (iv) assessment of lysozyme stabilization (11) . The results from these studies all indicate that introduction of N -glycan might be a promising method for obtaining protein mutants with moderately altered characteristics.
To date, however, remodeling proteins by N -glycosylation has required detailed information about the molecular structure of the subject protein and time-consuming construction of a large number of mutants. Our goal was to develop a method for introducing N -glycosylation sequences into proteins without having to pinpoint the insertion site. With the protocol described here, we successfully used a secreted form of fibroblast growth factor (FGF) as the target protein and a potential N -glycosylation sequence as the inserted functional sequence/domain. Further, this protocol should also be applicable to other proteins and other functional sequence/domain of interest.
Introduction of anN-Glycosylation Cassette into Proteins at Random Sites: Expression of Neoglycosylated FGF
BioTechniques 27:576-590 (September 1999) Chemicals (Osaka, Japan). Geneticin disulfate salt and RPMI 1640 powder were from Sigma (St Louis, MO, USA). Fetal bovine serum (FBS) was from Filtron Pty. Ltd. (Brooklyn, Australia).
Cell Culture
Mouse pro-B Ba/F3 cells were purchased from the Riken gene bank (Tsukuba, Ibaraki, Japan). The cells were grown in RPMI 1640 supplemented with 10% FBS and 10% WEHI-3 cell-conditioned medium (Riken gene bank) used as a source of interleukin-3.
Construction of a Model Protein to Introduce N-Glycosylation Sequence
An oligonucleotide encoding human FGF-1 αwas amplified by polymerase chain reaction (PCR) using primers No. 967 (5 ′ -gcgtc gacag cgcta attac aagaa gccca aactc-3 ′ ) and No. 630 (5 ′ -ccgaa ttcga attct ttaat cagaa gagac tgg-3 ′ ) and human FGF-1 cDNA as a template. The PCR product was digested with Sal I and Eco RI and subcloned into the Sal I/ Eco RI site of pBluescript ® II KS+ (Stratagene). This construct was designated FGF-1 α /pBS. A double-stranded (ds)DNA encoding a Kozak sequence and the signal peptide of mouse FGF-6 was amplified by PCR using primers No. 1048 (5 ′ -gcgtc gaccc accat gtccc gggga gcagg acgtg ttcag ggcac gctgc aggct ctcgt cttc-3 ′ ) and No. 968 (5 ′ -gcgat atcca gtagc gtgcc gttgg cgcg-3 ′ ) and mouse FGF-6 cDNA as a template. The PCR product was digested with Sal I and Eco RV and subcloned into the Aor 51HI and Sal I sites of FGF-1 α /pBS. This construct, encoding a secreted FGF [secFGF (N 35 )] that contains an Nglycosylation sequence derived from the original FGF-6 signal peptide, was designated secFGF(N 35 )/pBS. As our purpose was to detect N -glycosylation on the cassette newly introduced into the protein, the endogenous Asn 35 residue was substituted with Gln as described below. A dsDNA encoding a Kozak sequence and the signal peptide of mouse FGF-6, in which Asn 35 was substituted to Gln 35 , was amplified by PCR using primers No. 105 (5 ′ -gcgtc gaccc accat gtc-3 ′ ) and No. 124 (5 ′ -gcgat atcca gtagc gtgcc ttggg cgcg-3 ′ ) and mouse FGF-6 cDNA as a template. The PCR product was digested with Sal I and Eco RV and subcloned into the Aor 51HI and Sal I sites of FGF-1 α /pBS. This construct was designated secFGF/pBS. This cDNA construct was used in all the following study as the core construct to which the N -glycosylation cassette was introduced. Although the chimeric FGF protein encoded by this cDNA still contains one potential N -glycosylation sequence from the original FGF-1 primary structure (Asn 149 GlySer), N -glycosylation of this sequence was found to be of very low level (M. Asada et al., unpublished data).
DNase I Digestion
Ten micrograms of secFGF/pBS in 100 µ L of 50 mM Tris-HCl (pH 7.5) with 100 µ g/mL bovine serum albumin (BSA) and 10 mM MnCl were digested with DNase I (1.4 mU) at 37°C. Aliquots of the reaction mixture were sampled at various times and mixed with 1 µ L of 0.5 M EDTA (pH 8.0) to stop the reaction. The digests were resolved by electrophoresis on 1.4% agarose gels containing ethidium bromide in 1 ×40 mM Tris-acetate with 1 mM EDTA (pH 8.0). Appropriately sized DNA was excised from the gel, purified using SUPREC-01 and dissolved in 10 mM Tris-HCl with 1 mM EDTA (pH 8.0).
Preparation of Probes and Southern Blotting
Probes used for Southern blot analysis were prepared from the secFGF cDNA digest using restriction enzymes. secFGF cDNA was amplified by PCR using secFGF/pBS as a template with primers No. 115 (5 ′ -aacaa aagct gggta ccggg-3 ′ ) and No. 116 (5 ′ -gccgc tctag aacta gtggat-3 ′ ). Aliquots of the product were digested with Nae I/ Sal I or Hin fI/ Eco RI: the former yielded a 103-bp fragment that served as the 5 ′ -terminal section of the secFGF cDNA, and the latter yielded a 69-bp fragment that served as the 3 ′ -terminal section. The fragments were purified and labeled with digoxygenin using a DIG DNA labeling kit according to the manufacturer's instructions (Roche Molecular Biochemicals). DNA transfer onto nylon Hybond-N+ membranes, hybridization with probes and detection using antidigoxygenin-POD Fab fragment were performed as described previously (9) .
Preparation of cDNA Cassettes that Encoded the Potential N-Glycosylation Sequence
Three inserts with differing reading frames, each encoding a potential N -glycosylation sequence (AsnLeuSer) and a chloramphenicol resistance gene (Cm r ) removable by digestion with Afl II, were generated by PCR. To accomplish this, a Cm r cDNA template was amplified with PfuDNA polymerase using the following primers. For the 3n fragment, the primers were forward (5 ′ -gcgcg cgtta actta agcat cggca cgtaa gaggt tccaa ctt-3 ′ ) and reverse (5 ′ -atata agcgc ttaag ttacg ccccg ccctg ccact ca-3 ′ ); for the 3n+1 fragment, forward (5 ′ -gcgcg cgttt aaact taagc atcgg cacgt aagag gttcc aactt-3 ′ ) and reverse (5 ′ -atata tatcc cgggc ttaag ttacgc cccgc cctgc cact-3 ′ ); and for the 3n+2 fragment, forward (5 ′ -atata tcgcg aactt aagca tcggc acgta agagg ttcca ac-3 ′ ) and reverse (5 ′ -atata tatgc cggct taagt tacgc cccgc cctgc cactca-3 ′ ). Each PCR product was digested with Klenow enzyme (Takara Shuzo) and ligated into the Eco RV site of pBluescript SK+ treated with calf intestine alkaline phosphatase (Takara Shuzo), and each insert fragment was cleaved from its respective construct by digestion with the following sets of enzymes. The 3n fragment was obtained by digestion with Hin cII and Aor 51HI; 3n+1 by digestion with Pme I and Sma I; and 3n+2 by digestion with Nru I and Nae I. Each fragment was then purified using GENECLEAN II and resuspended in TE buffer.
Ligation of a cDNA Cassette Encoding an N-Glycosylation Sequence into a DNase I-Treated Plasmid
The inserts were then individually ligated with DNase-treated plasmids. E. coliDH5 αwere transformed by each product and selected for chloramphenicol (Cm) and ampicilin (Amp) resistance. Plasmids were prepared by the alkaline-sodium dodecyl sulfate (SDS) method and digested with Afl II to remove Cm r . Plasmids free of the Cm r gene were purified and recircularized by ligation under dilute conditions. The recircularized plasmids were digested with Sal I/ Eco RI to isolate the inserts containing the cDNA encoding the secFGF proteins with N -glycosylation sequences. The inserts were then further purified using SUPREC-01 enabling subsequent subcloning into an expression vector.
Construction of secFGF cDNA Harboring an N-Glycosylation Sequence at Predetermined Sites
For purposes of comparison, two additional forms of secFGF with an Nglycosylation cassette were constructed. The "A" form harbored a potential N -glycosylation sequence at the N terminus of the FGF-1 α portion. Its cDNA was constructed by the overlapping extension method using PCR and cloned PfuDNA polymerase. The 5 ′ half fragment was generated by PCR using primers No. 115 and No. Ntr (5 ′ -attag cactt aagtt atcca gtagc gtgcc ttg-3 ′ ) and secFGF/pBS as a template, while the 3 ′ half was generated using the same template and primers No. 116 and No. Ntf (5 ′ -ctgga taact taagt gctaa ttaca agaag ccc-3 ′ ). Equal aliquots of the reactants were mixed, and PCR was performed using primers No. 115 and No. 116. The final product was digested with Sal I/ Eco RI, purified and subcloned between the Sal I/ Eco RI sites of pBluescript KS+ vector. The "F" form harbored a potential N -glycosylation sequence at the C terminus of secFGF. The cDNA for F-form secFGF was generated by PCR using cloned Pfu DNA polymerase, secFGF/pBS as a template and primers No. 115 and C term reverse (5 ′ -gcgcg cgaat tctta gctta agtta tcaga agaga ctggc ag-3 ′ ). The reaction product was digested with Sal I/ Eco RI, purified and subcloned between the Sal I/ Eco RI sites of pBluescript KS+ vector.
Sequence Analysis and Construction of Expression Vectors
Nucleotide sequences were analyzed using the dideoxynucleotide chain termination method with a Model 373S DNA sequencer (PE Biosystems). Selected cDNA clones were isolated by digestion with Sal I/ Eco RI and subcloned between the Sal I/ Eco RI sites of pMEXneo, an eukaryotic expression vector. The secFGF is a chimera composed of the mutated signal peptide from mouse FGF-6 and the N-terminal truncated form of human FGF-1. The cDNA was cloned in pBlueScript (pBS). Digestion with DNase I in the presence of Mn 2+ generates secFGF cDNAs containing a single blunt end cut at various sites. Nglycosylation cassettes in three different frames containing Cm r were ligated into the blunt end cuts. E. coli were transformed by the ligation products, and colonies were selected on Cm/Amp LB plates. Plasmids prepared from selected colonies were digested with Afl II to remove Cm r , recircularized and cloned.
A

Transfection
Ba/F3 cells [1.5 ×10 6 in 150 µ L of phosphate-buffered saline (PBS)] were transfected with 8 µ g of expression plasmid by electroporation and suspended in RPMI 1640 medium supplemented with 10% FBS and 10% WEHI-3-conditioned medium. After two days in culture, the transfected cells were provided with fresh growth medium containing geneticin disulfate salt (1 mg/mL) and cultured for an additional two weeks to select stable transfectants.
Analysis of the Expressed FGF Proteins
To detect FGF proteins secreted into the culture medium, 40 µ L of heparin sepharose CL6B gel equilibrated with PBS were added to 2 mL of the conditioned medium from each transfectant culture and incubated at 4°C overnight. For the transfectants B, C, D and E, 9 mL of the conditioned medium was used. After washing with PBS twice, the beads were then boiled in 40 µ L of SDS-polyacrylamide gel electrophoresis (PAGE) sample buffer for 10 min, and the dissociated proteins were analyzed by SDS-PAGE.
To detect intracellular FGF proteins, the cells (ca. 5 × 10 5 ) were lysed on ice for 5 min in 100 µ L of lysis buffer, consisting of 10 mM Tris-buffered saline (TBS) (pH 7.5) containing 1% Nonidet ® P-40 (Iwai Kagaku, Ltd., Tokyo, Japan). The lysates were centrifuged, and the supernatants were recovered, mixed with SDS-PAGE sample buffer and boiled for 10 min. The samples were then centrifuged again, and the same quantity of FGF proteins in cleared supernatants were resolved by SDS-PAGE on 13% polyacrylamide gels attached with 3% stacking gels (6). After electrophoresis, the resolved proteins were electroblotted onto nitrocellulose membranes (Optitran ® BA-S 85 reinforced NC, 0.45 µ m; Schleicher & Schuell, Dassel, Germany). The membranes were blocked with 3% skim milk (dehydrated; Becton Dickinson Microbiology Systems, Sparks, MD, USA) in TBS for 1 h at room temperature and then incubated with 1 µ g/mL anti-FGF-1 monoclonal antibody (mAb-1) (3) in TBS containing 3% skim milk overnight at 4°C. The membranes were then washed three times with 0.05% Tween ® 20 in TBS and incubated at room temperature for 1 h with affinitypurified goat anti-mouse IgG conjugated with horseradish peroxidase (Chemicon International, Temecula, CA, USA). After washing, the signals were detected using an ECL ™Detection Kit (Amersham Pharmacia Biotech).
PNGase Digestion
The expressed FGF proteins contained in the lysates of the transfectants were adjusted to equal amounts and 
RESULTS
DNase I Digestion of secFGF cDNA Generating Single Cuts at Random Sites
Human FGF-1 was selected as a model protein into which a potential Nglycosylation sequence would be introduced. To enable the expressed proteins to be efficiently secreted, a signal peptide was introduced at the N terminus along with a single alanine used as a linker. An oligonucleotide encoding mouse FGF-6 signal peptide (the N terminal 40 amino acids) was fused to the 5 ′ terminus of cDNA of FGF-1 α , an Nterminal truncated form of FGF-1 (22-155) with full mitogenic activity, as shown in Figure 1A .
The critical step in the procedure is to randomly introduce a potential Nglycosylation sequence into the polypeptide core of secFGF (Figure 1) . Therefore, we first established a protocol for creating single blunt cuts at random sites in the secFGF cDNA using DNase I, which in the presence of Mn 2+ cleaves the two DNA strands at approximately the same site yielding fragments that are blunt-ended or that have protruding termini of only one or two nucleotides (8) . Controlled digestion at 37°C for selected times generated a single-cut form ( Figure 2A, lanes 2-7, To test whether the DNase I digestion had cut the plasmid randomly, the DNA bands corresponding to the single-cut form (Figure 2A , lanes 3-6, arrow b) were excised from the gel, and the DNA was purified, resolved on an agarose gel, transferred to a nylon membrane and hybridized with a digoxygenin-labeled probe targeting the 3 ′ terminus of secFGF cDNA ( Eco RI, which was unique in the plasmid, it was fractionated into smear bands ( Figure 2B, lane 2, long bracket) , indicating that the sites of DNase I digestion were distributed randomly over the plasmid. To further confirm that the secFGF cDNA was cut randomly, the purified single-cut DNA was digested with Eco RI and Sal I, an enzyme combination that digests both ends of the secFGF cDNA. This reaction generated a population of variably-sized DNA fragments ( Figure 2B, lane 3, short  bracket) , all of which were smaller than secFGF ( Figure 2B , lane 3, black arrowhead) and indicative of the random distribution of DNase I cleavage sites.
Preparation of cDNA Cassettes Encoding a Potential N-Glycosylation Sequence
To introduce the potential N -glycosylation sequence (AsnLeuSer) into the blunt-end cuts created by DNase I digestion, we designed cDNA cassettes in three possible frames that encode AsnLeuSer when matched ( Figure 1B) addition of amino acids, the AsnLeuSercoding sequence was divided in two by the Cm r gene so that after removal of this selection gene, the entire cassette encoded only one amino acid at most, in addition to AsnLeuSer. With three sets of oligonucleotide primers that differed in frame, three different cassettes were generated by PCR using the Cm r gene as a template ( Figure 1B) . The PCRgenerated cassettes were first cloned into the Eco RV site of pBluescript plasmids, and a plasmid was selected for each frame only after sequence verification. The respective N -glycosylation cassettes in the three-frame format were then cleaved from each plasmid using sets of restriction enzymes as described in Materials and Methods.
Ligation of N-Glycosylation Cassettes and the Selection of Clones Encoding secFGF with an N-Glycosylation Sequence
The N -glycosylation cassettes were ligated with the single-cut plasmids originally encoding secFGF. The ligation products were then used to transform Escherichia coli cells, and approximately 400 independent transformant colonies were obtained by selection on plates containing both ampicillin and chloramphenicol. Plasmids were prepared from the individual colonies, and the sizes of the inserts were examined by the digestion with Xho I/ Xba I.
Fifty clones were found to contain secFGF mutants of approximately 1250 bp, suggesting that the N -glycosylation cassettes were successfully inserted into the open reading frame of secFGF. In contrast, some clones were found to contain inserts that were equal in size to secFGF or at least smaller than 1250 bp. These smaller inserts likely derived from double-cut secFGF cDNA. The mutant secFGF cDNA clones were digested with Afl II to remove Cm r and were recircularized by self-ligation under dilute conditions. Unsuccessful clones were not pursued further. Nucleotide sequences of the recircularized clones were determined by restriction enzyme digestion and direct sequencing, which identified 21 mutated secFGF clones that had successfully incorporated AsnLeuSer-coding nucleotides without loosing the original secFGF nucleotide sequence. Indeed, 4 of the 21 clones encoded secFGF, in which the potential N -glycosylation sequence (AsnLeuSer) was encoded in frame at random sites (Figure 3, arrows B, C, D and E) . Table  1 summarizes the local amino acid sequences of the four clones deduced from their nucleotide sequences. For clones A and F, the N -glycosylation consensus sequence was respectively inserted at the N or C terminus in the same format as the other clones.
Expression of the N-Glycosylation
Sequence-Introduced secFGF Proteins in Mammalian Cells
The inserts encoding secFGF with the attached potential N -glycosylation sequences (AsnLeuSer) were individually subcloned from the cloning vector to a pMEXneo expression vector (4) and then transfected into Ba/F3 cells. The culture medium and cell bodies of the transfectants were collected and analyzed for expression of secFGF proteins. Analysis of the cell lysates revealed that all of the cDNA clones were successfully translated into proteins exhibiting secFGF antigenicity ( Figure   4A ). Further, most of these proteins were secreted by the transfectants; one exception, the translate of clone B was not detected in the conditioned culture medium ( Figure 4B) .
Analysis of the secreted proteins on SDS-PAGE followed by immunoblotting revealed that portions of the C, D and E forms of the secFGF mutants and ) all migrated as though they were of greater molecular mass than the simple secFGF protein, suggesting the presence of modification groups on these proteins. In contrast, modification of the A and F forms were not apparent ( Figure 4B) . Interestingly, the B-form mutant was detected in the lysate as a heavily modified protein ( Figure 4A ), even though it was not detected in the conditioned medium (Figure 4B) .
To investigate the nature of the modifications found on the various secFGF mutants, they were digested with PNGase and subjected to SDS-PAGE ( Figure 4C ). After digestion, all of the mutants, including the B form, migrated on SDS-PAGE in a manner indicating the same molecular mass as the original secFGF. This confirmed that the modifications found on all of the mutants were N -glycans. Because the potential endogenous N -glycosylation sequence at Asn 149 was modified at very low level in our earlier studies (M. Asada et al., unpublished data), most likely N -modifications of the C, D and E forms took place only on the newly introduced N -glycosylation cassettes. With respect to the B-form mutants, the excessively high glycosylation levels and the appearance of higher molecular mass bands ( Figure 4A ) suggests that the RDTNLSRSD sequence created in this construct (Table 1) is a very efficient acceptor for N -glycosylation.
DISCUSSION
Since the discovery of the N -glycosylation consensus sequence (7), its addition to or deletion from a large number of proteins has been attempted only by targeted mutagenesis. However, detailed structural information has been required to successfully carry out the insertion. Random introduction of an N -glycosylation sequence into a protein may thus be a powerful new approach to remodeling proteins for which structural data are not available or structural changes are not predictable. As there is no practical limitation on the degree to which the scale of our protocol can be expanded, it could, in principal, provide a cDNA library for all neoglycosylated proteins. Because the method does not depend on the presence of specific restriction enzyme sites, multiple clones expressing proteins with novel glycosylation sites can be generated by a single approach. This procedure is most useful for characterizing secreted proteins or transmembrane proteins with only one transmembrane domain. These proteins impose little constrain on the position at which the glycosylation site might be inserted. However, transmembrane proteins with several transmembrane domains allow the yKeynote Speakers y insertion of a glycosylation site only outside the hydrophobic membraneembedded sequences. PCR-based methods, which offer the possibility to insert additional amino acids at specific sites, will work better in these cases.
Recently, a method for a random insertion of a fluorescent protein into the regulatory subunit of cAMP-dependent protein kinase was developed to obtain information about the enzyme's functional domains (2) . However, it is not applicable for introducing a short peptide like AsnLeuSer, nor does it provide a method to adjust translation frames. Methods for random insertion of a short peptide has not been reported. Thus, the system described here offers many advantages over the earlier methods (10) .
In our experiments, the N -glycosylated proteins comprised only a fraction of the expression products for most of the constructs. Kasturi et al. (5) reported that the efficiency of the N -glycosylation of a rabies virus glycoprotein increased when AsnXaaSer was substituted with AsnXaaThr. Therefore, using an N -glycosylation cassette with higher efficiency than our present AsnLeuSer cassette may improve the yield of glycosylated forms. However, efficiency and specificity of glycosylation is also dependent on many cellular factors including the expression levels of glycosyl transferases and transporters, and the activity of the synthetic pathway for the sugar precursors. This makes establishing a glycoprotein production system capable of complete addition of a uniform oligosaccharide moiety a subject for continued future study.
Finally, because no FGF-specific or N -glycosylation sequence-specific structural characteristics were necessary by the protocol, with minor modification, the method described here should also be applicable to any other combination of protein and oligopeptide/polypeptide cassette of interest.
